Mental Health

Official Title

Uncertainty and Firearms: Obtaining Secure Storage (UFOS)

Purpose

The purpose of this study is to examine whether fear of uncertainty plays a role in home safety practices among firearm owners who are currently or have recently served in the U.S. military.

Could this study be right for you?

• Currently serving in any Branch or Component of the U.S. military, or were discharged from the U.S. military within the past 90 days
• 18 years or older
• Own at least one firearm located in your home or vehicle
• Are able to speak and understand the English language
• Have an Apple or Android smartphone 

Age Range

18 - 99 years

Official Title

Treatment of Stress and Anxiety in mild cognitive impairment (MCI)/Mild Alzheimer's Disease and related dementias (ADRD) and their care partners: A Randomized Controlled Trial

Purpose

The purpose of this study is to assess the impact of a treatment on anxiety and stress in individuals with memory concerns and those already with a diagnosis of Mild Cognitive Impairment (MCI), Mild Alzheimer's Disease and related dementias. 

Could this study be right for you?

The primary participant must:
· Be at least 60 years of age
· Have a “care-partner” that is willing to participate in the full program (such as a spouse, child or a good friend)
· NOT have a terminal illness or severe motor impairment
· Be able to use a computer and smartphone and read English at the 6th grade level

The care partner must:
· Be at least 18 years of age
· Be able to use a computer and smartphone and read English at the 6th grade level

Age Range

60 - 99 years

Official Title

BUckeye Concussion Knowledge Survey (BUCKS)

Purpose

The purpose of this study is to examine health outcomes in former Ohio State University athletes who played a varsity sport during their time at OSU. The objective is to determine whether athletes who sustained a concussion have different health outcomes than those who did not sustain a concussion. Any former OSU varsity athlete can participate in a 20-minute online survey.

Could this study be right for you?

• Anyone who has played a varsity sport as an undergraduate student at OSU, and they have now graduated (i.e., OSU athlete alumni). There are no other restrictions in terms of age, sex/gender, type of sport, etc.

Age Range

18 years and up

Official Title

Addressing the double jeopardy of stress and hypertension among African American female caregivers of persons living with Alzheimer’s disease and related dementias (R21)

Purpose

The purpose of this study is to determine the feasibility of a group delivered intervention for stress and blood pressure in African American women caregivers.

Could this study be right for you?

• Diagnosis of HTN treated with an antihypertensive medication or risk of HTN that includes obesity and high cholesterol
• Age 40 and older
• A caregiver rating of the PLWD of 2 or greater on the Alzheimer’s Dementia-8 scale
• Caregiver provides unpaid care to a PLWD at least 10 hours per week or assists with at least one instrumental activity of daily living
• Self-identifies as Black/African American
• English speaking
• Access to a telecommunications device such as the internet via desktop, laptop/tablet, smartphone, or telephone

Age Range

40 and up

Official Title

Orexin Receptor Antagonists as Modulators of Threat Sensitivity in individuals with Alcohol Use Disorder

Purpose

The purpose of this study is to see if BELSOMRA, an FDA approved medication that is prescribed to treat insomnia, changes the body’s response to stress. Participation in the study includes 3 or 5 in-person lab visits (depending on randomization), which include EEG and MRI. Nearly all visits are 1.5 hours long, with the exception of one that is 4-5 hours in duration. Visits are flexible and scheduled at your convenience. Participants take the medication (or placebo) for 4 weeks, during which participation is only composed of virtual surveys via a smartphone app.

The total length of participation in the study is 1.5-2 months depending on scheduling/availability.

Could this study be right for you?

Eligibility Criteria:

• 18-65 years old
• Generally medically and physically healthy
• Regular alcohol use

Exclusion Criteria:

• Diagnosis of bipolar disorder, schizophrenia, mania, or psychosis
• Currently pregnant or trying to become pregnant (female)
• Presence of ferrous-containing metal in the body
• Inability to tolerate enclosed spaces
   

Exclusion Criteria varies, please contact Study Coordinator for more information.

Age Range

18 - 65

Official Title

Ontogenesis of Categorization; Linking development, mechanisms, and biology

Purpose

The purpose of this study is to investigate the early development of attention, learning, and memory during childhood. Participation in this study includes 4, 90-minute-long visits to the lab per year. During these visits, your child will play 2-3 fun, computerized games. These games are designed to assess various aspects of their cognitive ability. 

The duration of the study will last 4 years.

Could this study be right for you?

Eligibility Criteria: 

• African-American/Black children who are 4 years old 

Age Range

4 - 4

Official Title

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Purpose

The purpose of the study is to determine if the investigational study drug will rapidly reduce depression associated with thoughts of harming oneself when given in addition to standard antidepressant medication.

Your participation in this study will last for a minimum of 14 weeks and maximum of 58 weeks.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosed with major depressive disorder (MDD) with a current major depressive episode
• Having current suicidal ideation with intent
• Already in the hospital or agree to be hospitalized voluntarily for the required period of time

Age Range

18 and up

Official Title

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Purpose

This study is being done to see if the study drug, called BI 1358894, compared to a drug called quetiapine, may help people with Major Depressive Disorder (MDD) who do not progress when taking an antidepressant medication alone. This study will help to gain information for providing better or new possible treatments for people in the future.

This study will take place over a period of 13 weeks and have about 8 visits to the study center and 2 that will be done by phone.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosed with Major Depressive Disorder (MDD)
• Currently depressed
• Taking an antidepressant

Age Range

18 and up

Official Title

Safety of REL-1017 for Major Depressive Disorder (RELIANCE-OLS)

Purpose

This is a 1-year open-label study to access the safety of REL-1017, a study medication, once daily as a workable treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug for the duration of the treatment period.

This study will last 13 months and you will come to the study site at least 15 times over this period. This will include 1 final visit about 1 month after you stop taking the study drug.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosed with Major Depressive Disorder (MDD)
• Currently depressed
• Taking or having taken between 1 and 3 antidepressants for the current episode of depression

Age Range

18 and up

Official Title

Study to Assess the Efficacy and Safety of Adjunctive NBI-1065845 in Adults with Major Depressive Disorder (MDD) (SAVITRI)

Purpose

The purpose of this study is to evaluate the effectiveness and safety of NBI-1065845 compared with placebo. In addition to the study drug, participants will continue their normal antidepressant medications. The main goal of this study is to examine the improving symptoms of depression.

The duration of the study will last 14 weeks, including up to 4 weeks of screening, 8 weeks of study drug dosing, and a follow-up period of 2 weeks.

Could this study be right for you?

• Aged 18-65 years old
• Have a diagnosis of Major Depressive Disorder (MDD)
• Currently depressed
• Poor response to antidepressant treatment

Age Range

18 and up